148 related articles for article (PubMed ID: 31313879)
1. Artifactual Kappa Light Chain Restriction of Marrow Hematogones: A Potential Diagnostic Pitfall in Minimal Residual Disease Assessment of Plasma Cell Myeloma Patients on Daratumumab.
Jiang XY; Luider J; Shameli A
Cytometry B Clin Cytom; 2020 Jan; 98(1):68-74. PubMed ID: 31313879
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis.
McSweeney PA; Wells DA; Shults KE; Nash RA; Bensinger WI; Buckner CD; Loken MR
Blood; 1996 Jul; 88(2):622-32. PubMed ID: 8695810
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
[TBL] [Abstract][Full Text] [Related]
4. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
[TBL] [Abstract][Full Text] [Related]
5. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
[TBL] [Abstract][Full Text] [Related]
6. VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.
Courville EL; Yohe S; Shivers P; Linden MA
Am J Clin Pathol; 2020 Jan; 153(2):221-228. PubMed ID: 31679012
[TBL] [Abstract][Full Text] [Related]
7. CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.
Minarik J; Novak M; Flodr P; Balcarkova J; Mlynarcikova M; Krhovska P; Pika T; Pikalova Z; Bacovsky J; Scudla V
Eur J Haematol; 2017 Aug; 99(2):186-189. PubMed ID: 28470777
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
Stocker N; Gaugler B; Ricard L; de Vassoigne F; Marjanovic Z; Mohty M; Malard F
Cancer Med; 2020 Mar; 9(6):2077-2084. PubMed ID: 31991058
[TBL] [Abstract][Full Text] [Related]
9. An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells.
Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Ikemoto T; Tanaka H; Nishimura Y; Tsuji M; Hanafusa T
Diagn Pathol; 2012 Sep; 7():131. PubMed ID: 23021410
[TBL] [Abstract][Full Text] [Related]
10. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
12. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.
Ogiya D; Liu J; Ohguchi H; Kurata K; Samur MK; Tai YT; Adamia S; Ando K; Hideshima T; Anderson KC
Blood; 2020 Nov; 136(20):2334-2345. PubMed ID: 32844992
[TBL] [Abstract][Full Text] [Related]
13. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
[TBL] [Abstract][Full Text] [Related]
14. The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia.
Babusíková O; Zelezníková T; Mlcáková A; Kusenda J; Stevulová L
Neoplasma; 2005; 52(6):502-9. PubMed ID: 16284697
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters.
Gupta S; Karandikar NJ; Ginader T; Bellizzi AM; Holman CJ
Cytometry B Clin Cytom; 2018 May; 94(3):500-508. PubMed ID: 29316245
[TBL] [Abstract][Full Text] [Related]
16. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.
van Velzen JF; van den Blink D; Bloem AC
Cytometry B Clin Cytom; 2013; 84(1):30-2. PubMed ID: 23019187
[TBL] [Abstract][Full Text] [Related]
17. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model.
Cannizzo E; Carulli G; Del Vecchio L; Ottaviano V; Bellio E; Zenari E; Azzarà A; Petrini M; Preffer F
Am J Clin Pathol; 2012 Mar; 137(3):377-86. PubMed ID: 22338049
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.
Nijhof IS; Groen RW; Lokhorst HM; van Kessel B; Bloem AC; van Velzen J; de Jong-Korlaar R; Yuan H; Noort WA; Klein SK; Martens AC; Doshi P; Sasser K; Mutis T; van de Donk NW
Leukemia; 2015 Oct; 29(10):2039-49. PubMed ID: 25975191
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
[TBL] [Abstract][Full Text] [Related]
20. Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome.
Santiago V; Lazaryan A; McClune B; McKenna RW; Courville EL
Leuk Lymphoma; 2018 Apr; 59(4):958-966. PubMed ID: 28728454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]